1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Acrux Limited

Acrux Limited

ARUXF
Acrux LimitedUS flagOther OTC
0.00
USD
- -
- -
1.32MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
0.32
0.15
0.17
0.14
0.02
- -
0.01
0.01
0.01
0.03
0.02
- -
0.01
Basic EPS, GAAP
0.17
0.07
0.08
- -
-0.09
-0.05
-0.06
-0.06
-0.03
- -
-0.02
-0.02
- -
Free Cash Flow per Basic Share
0.22
0.06
0.1
0.03
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.2
0.08
0.06
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.25
0.24
0.26
0.26
0.18
0.13
0.08
0.07
0.03
0.03
0.01
- -
- -
Tangible Book Value per Share
0.25
0.12
0.15
0.22
0.18
0.13
0.07
0.06
0.03
0.03
0.01
- -
- -
Basic Weighted Avg Shares
167
167
167
167
167
167
168
220
284
286
289
352
423
Sales/Revenue/Turnover
53
25
28
23
3
1
1
1
2
8
5
1
4
Operating Margin (%)
87
68.71
68.92
45.31
-408.67
-2,058.64
-963.85
-1,215.48
-754.28
-40.22
-168.43
-753.95
-57.82
Depreciation Expense
1
1
1
2
1
- -
1
1
1
1
1
- -
- -
Net Income, GAAP
28
11
13
- -
-14
-8
-9
-13
-10
-1
-6
-6
-1
Effective Tax Rate (%)
36.22
33.77
28.25
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
52.41
45.21
46.35
-1.04
-527.8
-1,319.33
-755.87
-944.58
-572.08
-9.06
-113.93
-499.58
-14.05
Working Capital
25
25
28
36
26
19
10
16
7
8
2
- -
1
LT Debt
- -
- -
- -
- -
- -
- -
2
2
2
2
2
2
1
Total Equity
42
41
44
44
30
22
13
18
9
9
3
1
1
Return on Invested Capital (%)
62.33
25.18
30.85
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
62.99
26.92
30.72
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
62.99
26.92
30.72
-0.55
-38.38
-32.08
-54.45
-80.64
-71.36
-8.59
-96.89
-276.58
-48.51

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-19.9%
-28.56%
43.4%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
609.76%
91.49%
-89.84%
Sales/Revenue/Turnover
48.74%
112.77%
261.18%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
5
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
4

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.02
2025
- -
- -
- -
- -
-0.02
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
John Warmbrunn
Full Time Employees
43
Sector
Healthcare
Industry
Biotechnology
Address
103-113, Stanley Street West Melbourne VIC Australia 3003
IPO Date
Jun 8, 2010
Website
acrux.com.au
Similar Companies
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO)
Cardiff Oncology, Inc. (CRDF)
Wave Life Sciences Ltd. (WVE)
Carisma Therapeutics, Inc. (CARM)
Hemostemix Inc. (HMTXF)
Hyundai Bioscience Co., Ltd. (048410.KQ)
Business
Acrux Limited (ASX:ACR; OTC:ARUXF) develops, registers and commercializes topically applied generic pharmaceutical products, with a primary focus on the US market through FDA-approved Abbreviated New Drug Applications (ANDAs); core offerings include Prilocaine 2.5% and Lidocaine 2.5% Cream, a topical anesthetic; Evamist, an estradiol spray for menopause symptoms; Dapsone 5% Gel and Dapsone 7.5% Gel, treatments for acne vulgaris; Nitroglycerin 0.4% Ointment for chronic anal fissure pain; and a pipeline of 16 products at stages from formulation development to commercialization, targeting conditions such as fungal toenail infections and cold sores. The company, founded in 1998 and headquartered at 103-113 Stanley Street, West Melbourne, Australia, operates principally in Australia and the United States, leveraging on-site laboratories and GMP manufacturing. Recent developments encompass FDA approvals for Dapsone 7.5% Gel in August 2024 and Nitroglycerin 0.4% Ointment in December 2024, with partner-led launches of Nitroglycerin in December 2024 and planned Dapsone 7.5% rollout in fiscal 2025; a $4.0 million capital raise via placement and share purchase plan in December 2024, including attaching options exercisable at 5.25 cents through February 2027; receipt of $2.975 million in R&D tax incentives for fiscal 2024; introduction of a 90mg pack for Dapsone 5% Gel in December 2024; and announcement in February 2025 of CEO Michael Kotsanis' planned retirement pending successor appointment.